Option Finance

Option Finance

ADVICENNE : nomination à la tête du développement clinique aux États-Unis
Capital.fr

Capital.fr

Advicenne : exercice partiel de l’option de surallocation
BFM BUSINESS

BFM BUSINESS

Intégrale Bourse (intervention Luc-André Granier à 30 :05’)
Easybourse.com

Easybourse.com

Interview de Caroline Roussel-Maupetit “Notre volonté est de rendre notre traitement accessible au plus grand nombre”
Le Revenu TV

Le Revenu TV

Luc-André Granier : «Advicenne va lui-même vendre ses médicaments»
La Tribune

La Tribune

La biotech Advicenne veut lever 30 millions d’euros en Bourse
LaBiotech.eu

LaBiotech.eu

French Biotech Launches €30M IPO to be the First to Treat Rare Disease in Children
Les Echos

Les Echos

Advicenne se lance en Bourse pour vaincre les maladies rénales rares
Scrip.com

Scrip.com

Advicenne Launches IPO With Kidney Drug Close To Filing

Since its founding in 2007, Advicenne has been dedicated to developing and commercializing innovative treatments that address unmet medical needs in the area of nephrology. Our lead drug candidate, ADV7103, is in late-stage clinical trials for two indications: distal renal tubular acidosis (dRTA) and cystinuria. Listed on both the Euronext Paris and Euronext Brussels stock exchanges, the company is headquartered in Nîmes, France.

Contact Us

11 + 6 =

© 2019 Advicenne